ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2120

No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study

Xintong Li 1, Kathleen M Andersen2, Hsien-Yen Chang 3, G. Caleb Alexander 4 and Jeffrey Curtis 5, 1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, 3Johns Hopkins Bloomberg School of Public Health, Baltimore, 4Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD, 5University of Alabama at Birmingham, Birmingham, AL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: drug safety, interleukins (IL) and anti-TNF therapy, psoriasis, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: Infection-Related Rheumatic Disease Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The real-world risk of serious infections associated with interleukin (IL) and tumor necrosis factor-alpha (TNF-α) inhibitors for patients with psoriasis (PsO) and psoriatic arthritis (PsA) is unclear. The objective of this study was to examine whether initiation of IL-17, IL-12/23, or TNF-α, was associated with increased risk of serious infection among PsO and PsA patients.

Methods: We built a cohort of commercially insured adults diagnosed with PsO or PsA between 2015–2018 using data from the OptumLabs® Data Warehouse. Exposure was new use of IL-17 (ixekizumab or secukinumab), IL-12/23 (ustekinumab), or TNF-α (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab). The main outcome was hospitalized infection after date of biologic initiation. Incidence rates (IR) per 100 person-years were computed, and hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox proportional hazards regression models, adjusted for inverse probability of treatment weighted propensity scores to control for confounding. In sensitivity analyses, we varied the permissible gap between prescriptions, and to restrict to infection listed as the first diagnosis code position.

Results: A total of 11,560 new treatment episodes were included (19% IL-17, 25% IL-12/23, 56% TNF-α inhibitors). Overall, 190 serious infections (2% of treatment episodes) were identified in 9,264 person-years of follow-up (Table). Class-specific IR were similar among IL-17 and TNF- α, and significantly lower for IL-12/23. After adjustment for propensity scores, there was no evidence of an increased risk of serious infections with IL-17, as compared to either TNF-α (HR=0.89, 95% CI 0.48-1.66) or IL-12/23 (HR=1.12, 95% CI 0.62-2.03). By contrast, IL-23/23 were associated with a lower risk of infections than TNF-α (HR=0.59, 95% CI 0.39-0.90). In the subgroup of patients with PsA, we observed a similar risk of serious infections between the three biologics exposure groups. Indeed, compared to the PsA cohort, the PsO cohort patients were younger, more likely to be male, had fewer comorbidities, fewer physician office visits, lower proportions of DMARD use, and less glucocorticoid exposure during baseline. Nevertheless, we note that the effect estimate even in the PsA patients for IL-12/23 exposure was numerically lower (0.74 , 95% CI 0.40 – 1.36) and compatible with the significantly protective association observed in the psoriasis patients (0.59, 95% CI 0.38 – 0.92).

Conclusion: We did not find empirical evidence of an increased risk of serious infection with the IL-17 inhibitors, and observed a significantly lower infection risk with IL-12/23 biologics, compared to TNF- α therapy. Given the relatively small magnitude of absolute effect (difference less than 1 per 100 person-years) yet strong relative risk reduction compared to TNF-a, these results may inform clinical decision-making regarding the safety of the available choices.


ACR abstract Table


Disclosure: X. Li, None; K. Andersen, National Heart, Lung and Blood Institute (NHLBI) Pharmacoepidemiology T32 Training Program (T32HL139426-01)., 2, National Heart, Lung and Blood Institute Pharmacoepidemiology T32 Training Program (T32HL139426-01)., 2; H. Chang, None; G. Alexander, Chair of FDA’s Peripheral and Central Nervous System Advisory Committee, 9, Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation, 4, 5, OptumRx’s National P&T Committee, 6, Serves as a paid advisor to IQVIA, 5, This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.; J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Li X, Andersen K, Chang H, Alexander G, Curtis J. No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/no-evidence-of-an-increased-risk-of-serious-infections-among-3-classes-of-biologics-for-psoriasis-or-psoriatic-arthritis-a-retrospective-real-world-cohort-study/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/no-evidence-of-an-increased-risk-of-serious-infections-among-3-classes-of-biologics-for-psoriasis-or-psoriatic-arthritis-a-retrospective-real-world-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.